Skip to content

Journal of Psychopharmacology

ISSN 0269-8811, 1461-7285

521 papers in the library · 34,708 citations · publishing 1992-2026

Papers

Sort Most recent Most cited

Microdosing psychedelics: Demographics, practices, and psychiatric comorbidities

Journal of Psychopharmacology February 28, 2020 Daniel Rosenbaum, Cory R. Weissman, Thomas Anderson et al. 75 citations

Rationale: Microdosing psychedelics – the practice of consuming small, sub-hallucinogenic doses of substances such as LSD or psilocybin – is gaining attention in popular media but remains poorly characterized. Contemporary studies of psychedelic microdosing have yet to report the basic psychiatric descriptors of psychedelic microdosers. Objectives: To examine the practices and demographics of a...

The serotonin 2A receptor agonist 25CN-NBOH increases murine heart rate and neck-arterial blood flow in a temperature-dependent manner

Journal of Psychopharmacology February 12, 2020 Tobias Buchborn, Taylor Lyons, Chenchen Song et al. 11 citations

BACKGROUND: Serotonin 2A receptors, the molecular target of psychedelics, are expressed by neuronal and vascular cells, both of which might contribute to brain haemodynamic characteristics for the psychedelic state. AIM: Aiming for a systemic understanding of psychedelic vasoactivity, here we investigated the effect of N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine - a new-generation...

Nitrous oxide causes peripheral neuropathy in a dose dependent manner among recreational users

Journal of Psychopharmacology February 1, 2020 Adam Winstock, J. Ferris

Background: Nitrous oxide (N2O) has been used in clinical and recreational settings for over 150 years. Through inactivation of the Vitamin B12 dependent enzyme, methionine synthase, N2O can lead to the development of peripheral neuropathy. This study sought to determine the relationship between the exposure and risk of neurological symptoms in the largest ever sample of users. Design: Data are...

Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression

Journal of Psychopharmacology January 16, 2020 Lea J. Mertens, Matthew B. Wall, Leor Roseman et al. 211 citations

Background: Psilocybin has shown promise as a treatment for depression but its therapeutic mechanisms are not properly understood. In contrast to the presumed actions of antidepressants, we recently found increased amygdala responsiveness to fearful faces one day after open-label treatment with psilocybin (25 mg) in 19 patients with treatment-resistant depression, which correlated with...

Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer

Journal of Psychopharmacology January 9, 2020 Gabrielle Agin-Liebes, Tara C. Malone, Matthew M. Yalch et al. 353 citations

Background: A recently published randomized controlled trial compared single-dose psilocybin with single-dose niacin in conjunction with psychotherapy in participants with cancer-related psychiatric distress. Results suggested that psilocybin-assisted psychotherapy facilitated improvements in psychiatric and existential distress, quality of life, and spiritual well-being up to seven weeks prior...

Serotonin type 5A receptor antagonists inhibit D-lysergic acid diethylamide discriminatory cue in rats

Journal of Psychopharmacology November 1, 2019 Piotr Popik, Martyna Krawczyk, Agata Kuziak et al.

Purpose: Like other psychedelics, D-lysergic acid diethylamide (LSD) affects numerous serotonin receptors, and according to the current dogma, the 5-HT 2A receptors are considered the main target for its hallucinogenic effects. LSD, however, also displays agonistic activity at the 5-HT 5A receptors, which mediate some of LSD-induced behavioural effects. Methods: Using male Sprague Dawley rats,...

Prevalence and epidemiological associates of novel psychedelic use in the United States adult population.

Journal of Psychopharmacology September 1, 2019 James D. Sexton, Michael S Crawford, Noah W Sweat et al. 33 citations

Novel psychedelics approximate classic psychedelics, but unlike classic psychedelics, novel psychedelics have been used by humans for a shorter period of time, with fewer data available on these substances. The purpose of this study was to determine the prevalence of novel psychedelic use and the associations of novel psychedelic use with mental health outcomes. We estimated the prevalence of...

DOI: 10.1177/0269881119827796 (opens in new tab) Full text (opens in new tab) Hallucinogen Mental health Phenethylamines Novel psychedelic use +1

Developing a phone-based measure of impairment after acute oral ∆9-tetrahydrocannabinol.

Journal of Psychopharmacology September 1, 2019 Elisa Pabon, Harriet de Wit

Acute consumption of cannabis or its primary psychoactive ingredient ∆9-tetrahydrocannabinol has been shown to impair memory, reaction time, time perception, and attention. However, it is difficult to measure these impairments in a brief test that can be used in a non-laboratory setting. We aim to develop and validate a prototype for a mobile phone application to measure...

Effects of MDMA on neuroplasticity, amyloid burden and phospho-tau expression in APPswe/PS1dE9 mice.

Journal of Psychopharmacology September 2019 Sonia Abad, Carla Ramon-Duaso, Raúl López‐arnau et al.

3,4-Methylenedioxymethamphetamine (MDMA) is still one of the most consumed drugs by adolescents. Its abuse is related with cognitive impairment, which seems due to maladaptive plasticity and neural stress. In turn, new hypotheses suggest that Alzheimer's disease (AD) may be promoted by neural stressors. To test if there is an increase in vulnerability to AD after chronic MDMA consumption, we...

Exploring the munchies: An online survey of users’ experiences of cannabis effects on appetite and the development of a Cannabinoid Eating Experience Questionnaire

Journal of Psychopharmacology July 26, 2019 C. Roberts, G. Jager, P. Christiansen et al.

Background: Cannabis intoxication is commonly reported to increase appetite and enhance appreciation of food (the ‘munchies’). These effects are attributed to activation of the endocannabinoid system. However, the psychological changes that underlie these phenomena are under-researched. We report here the results of an extensive online survey of cannabis users with an exploratory Cannabinoid...

Microdosing psychedelics: More questions than answers? An overview and suggestions for future research

Journal of Psychopharmacology July 14, 2019 Livia Ng, Luca Pani, Anaïs Soula et al.

Background: In the past few years, the issue of ‘microdosing’ psychedelics has been openly discussed in the public arena where claims have been made about their positive effect on mood state and cognitive processes such as concentration. However, there are very few scientific studies that have specifically addressed this issue, and there is no agreed scientific consensus on what microdosing is....

Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory.

Journal of Psychopharmacology July 11, 2019 Leor Roseman, Eline Haijen, Kelvin Idialu-Ikato et al. 415 citations

Background: Psychedelic therapy is gaining recognition and the nature of the psychedelic experience itself has been found to mediate subsequent long-term psychological changes. Much emphasis has been placed on the occurrence of mystical-type experiences in determining long-term responses to psychedelics yet here we demonstrate the importance of another component, namely: emotional breakthrough....

DOI: 10.1177/0269881119855974 (opens in new tab) Psychedelics Hallucinogens Entheogens Mind-altering substances +16

Salvindolin elicits opioid system-mediated antinociceptive and antidepressant-like activities.

Journal of Psychopharmacology July 2019 Adam W Keasling, Pankaj Pandey, Robert J Doerksen et al.

Salvinorin A is known as a highly selective kappa opioid receptor agonist with antinociceptive but mostly pro-depressive effects. In this article, we present its new semisynthetic analog with preferential mu opioid affinity, and promising antinociceptive, as well as antidepressant-like activities. Competitive binding studies were performed for salvindolin with kappa opioid and mu opioid. The...

Cannabis-induced altered states of consciousness are associated with specific dynamic brain connectivity states

Journal of Psychopharmacology June 3, 2019 Yuliya Zaytseva, Jiřı́ Horáček, Jaroslav Hlinka et al. 25 citations

BACKGROUND: Cannabis, and specifically one of its active compounds delta-9-tetrahydrocannabinol in recreational doses, has a variety of effects on cognitive processes. Most studies employ resting state functional magnetic resonance imaging techniques to assess the stationary effects of cannabis and to-date one report addressed the impact of delta-9-tetrahydrocannabinol on the dynamics of...

DOI: 10.1177/0269881119849814 (opens in new tab) Cannabis Precuneus Delta-9-tetrahydrocannabinol Resting State FMRI +3

Cessation and reduction in alcohol consumption and misuse after psychedelic use

Journal of Psychopharmacology May 14, 2019 Albert Garcia‐romeu, Alan K. Davis, Fire Erowid et al. 286 citations

Background: Meta-analysis of randomized studies using lysergic acid diethylamide (LSD) for alcohol use disorder (AUD) showed large, significant effects for LSD efficacy compared to control conditions. Clinical studies suggest potential anti-addiction effects of LSD and mechanistically-related classic psychedelics for alcohol and other substance use disorders. Aims: To supplement clinical...

DOI: 10.1177/0269881119845793 (opens in new tab) Psilocybin Psychedelics Hallucinogens Severe alcohol misuse +4

Global brain volume reductions in a sub-chronic phencyclidine animal model for schizophrenia and their relationship to recognition memory

Journal of Psychopharmacology May 7, 2019 Nazanin Doostdar, Eugene Kim, Ben Grayson et al.

Background: Cognitive deficits and structural brain changes co-occur in patients with schizophrenia. Improving our understanding of the relationship between these is important to develop improved therapeutic strategies. Back-translation of these findings into rodent models for schizophrenia offers a potential means to achieve this goal. Aims: The purpose of this study was to determine the...

Metabolites of the ring-substituted stimulants MDMA, methylone and MDPV differentially affect human monoaminergic systems

Journal of Psychopharmacology April 30, 2019 Dino Luethi, Karolina E. Kolaczynska, Melanie Walter et al. 39 citations

Background: Amphetamine analogs with a 3,4-methylenedioxy ring-substitution are among the most popular illicit drugs of abuse, exerting stimulant and entactogenic effects. Enzymatic N-demethylation or opening of the 3,4-methylenedioxy ring via O-demethylenation gives rise to metabolites that may be pharmacologically active. Indeed, previous studies in rats show that specific metabolites of...

Dissociable effects of cannabis with and without cannabidiol on the human brain’s resting-state functional connectivity

Journal of Psychopharmacology April 23, 2019 Matthew B. Wall, Rebecca Pope, Tom P. Freeman et al. 89 citations

BACKGROUND: -tetrahydrocannabinol (THC) and cannabidiol (CBD). THC is the main psychoactive component; CBD may buffer the user against the harmful effects of THC. AIMS: We examined the effects of two strains of cannabis and placebo on the human brain's resting-state networks using fMRI. METHODS: Seventeen healthy volunteers (experienced with cannabis, but not regular users) underwent three drug...

Recreational use of psychedelics is associated with elevated personality trait openness: Exploration of associations with brain serotonin markers.

Journal of Psychopharmacology February 28, 2019 David Erritzøe, James Smith, Patrick M. Fisher et al. 95 citations

Background: Recent studies have suggested therapeutic benefits of psychedelics for a variety of mental health conditions. The understanding of how single psychedelic administrations can induce long-lasting effects are, in large, still lacking. However, recent studies in both healthy and clinical populations suggest a role for personality changes. Aim: To test support for some of these plausible...

DOI: 10.1177/0269881119827891 (opens in new tab) Psychedelics Recreational psychedelic experiences Recreational use Personality openness +6

What are the psychological effects of using synthetic cannabinoids? A systematic review

Journal of Psychopharmacology February 21, 2019 Hina Akram, Claire Mokrysz, Helen Valerie Curran 57 citations

BACKGROUND: Synthetic cannabinoids are, typically, full agonists at the cannabinoid CB1 receptor, and therefore considerably more potent than natural cannabis and may have correspondingly more serious psychological effects. Despite government sanctions against their production they continue to be available in ever-increasing varieties over the Internet. The psychological consequences of...

Comparison of the behavioral effects of mescaline analogs using the head twitch response in mice

Journal of Psychopharmacology February 21, 2019 Adam L. Halberstadt, Muhammad Chatha, Stephen J. Chapman et al. 25 citations

Background: In recent years, there has been increasing scientific interest in the effects and pharmacology of serotonergic hallucinogens. While a large amount of experimental work has been conducted to characterize the behavioral response to hallucinogens in rodents, there has been little systematic investigation of mescaline and its analogs. The hallucinogenic potency of mescaline is increased...

Greater empathy in MDMA users

Journal of Psychopharmacology February 5, 2019 Molly Carlyle, Tobias Stevens, Leah Fawaz et al. 22 citations

Background: 3,4-Methylenedioxymethamphetamine (MDMA) is widely known for its positive acute effects on social behaviour, such as increasing empathy, whilst also attenuating the negative impact of social exclusion. However there is a scarcity of research that investigates the long-term impact of recreational MDMA use on these fundamental social processes. Method: Sixty-seven individuals were...

Temporal dynamics of the pharmacological MRI response to subanaesthetic ketamine in healthy volunteers: A simultaneous EEG/fMRI study

Journal of Psychopharmacology January 21, 2019 Rebecca McMillan, Anna Forsyth, Doug Campbell et al. 23 citations

BACKGROUND: Pharmacological magnetic resonance imaging has been used to investigate the neural effects of subanaesthetic ketamine in healthy volunteers. However, the effect of ketamine has been modelled with a single time course and without consideration of physiological noise. AIMS: This study aimed to investigate ketamine-induced alterations in resting neural activity using conventional...

DOI: 10.1177/0269881118822263 (opens in new tab) Ketamine Blood-oxygen-level dependent Electroencephalography Anterior cingulate cortex +5

3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial.

Journal of Psychopharmacology December 1, 2018 Marcela Ot'Alora G, Jim Grigsby, Bruce Poulter et al. 232 citations

Posttraumatic stress disorder often does not resolve after conventional psychotherapies or pharmacotherapies. Pilot studies have reported that 3,4-methylenedioxymethamphetamine (MDMA) combined with psychotherapy reduces posttraumatic stress disorder symptoms. This pilot dose response trial assessed efficacy and safety of MDMA-assisted psychotherapy across multiple therapy teams. Twenty-eight...

DOI: 10.1177/0269881118806297 (opens in new tab) Full text (opens in new tab) Serotonin 3,4-Methylenedioxymethamphetamine MDMA Oxytocin Posttraumatic stress disorder +16

The dose-dependent psychomotor effects of intravenous delta-9-tetrahydrocannabinol (Δ9-THC) in humans.

Journal of Psychopharmacology December 2018 Douglas L Boggs, Jose A Cortes-Briones, Toral Surti et al.

Binding studies have demonstrated that levels of the cannabinoid receptor type-1 are highest in the basal ganglia and cerebellum, two areas critical for motor control. However, no studies have systematically examined the dose-related effects of intravenous delta-9-tetrahydrocannabinol, the primary cannabinoid receptor type-1 partial agonist in cannabis, on broad domains of psychomotor function...